ArticleNPJ cardiovascular health2026
Economic modeling of polygenic risk prediction of coronary artery disease in childhood.
Article in NPJ cardiovascular health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk factors and subclinical pathophysiology of coronary artery disease (CAD) begin in childhood, yet identifying candidates for primordial prevention remains challenging. Polygenic risk scores (PRS) provide a DNA-based risk marker from birth that can stratify children by lifetime CAD risk. We evaluated the potential clinical utility and cost-effectiveness of PRS-guided CAD prevention in children using health economic modeling. A Markov model compared PRS-guided prevention with standard prevention in a hypothetical group of 10,000 children. Children in the top 20% of PRS (n = 2000) were assumed to receive behavioral interventions. Assuming a 10-year CAD incidence of 12% during adulthood among those in the top 20% of the PRS distribution and a conservative 30% relative risk reduction with preventive intervention, PRS-guided prevention was projected to prevent 72 CAD events among 2000 high-risk children (3.6% absolute event reduction), yielding a return on investment of 3614%. PRS enables early, targeted prevention, improving outcomes, and lowering lifetime costs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.